{"content":"<li class=\"n-box-item date-title\" data-end=\"1562644799\" data-start=\"1562558400\" data-txt=\"Monday, December 23, 2019\">Monday, July  8, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3476360\" data-ts=\"1562621816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476360-ogi-frac-nbr-and-ddd-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OGI, FRAC, NBR and DDD among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/OGI' title='OrganiGram Holdings Inc.'>OGI</a> <font color=\"green\">+7.34%</font>. <a href='https://seekingalpha.com/symbol/MR' title='Montage Resources Corporation'>MR</a> <font color=\"green\">+5.42%</font>. <a href='https://seekingalpha.com/symbol/FRAC' title='Keane Group, Inc.'>FRAC</a> <font color=\"green\">+4.95%</font>. <a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a> <font color=\"green\">+4.78%</font>. <a href='https://seekingalpha.com/symbol/UXIN' title='Uxin Limited'>UXIN</a> <font color=\"green\">+4.78%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/WAAS' title='AquaVenture Holdings Limited'>WAAS</a> <font color=\"red\">-5.79%</font>. <a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corporation'>DDD</a> <font color=\"red\">-4.14%</font>. <a href='https://seekingalpha.com/symbol/NMFC' title='New Mountain Finance'>NMFC</a> <font color=\"red\">-2.93%</font>. <a href='https://seekingalpha.com/symbol/EGRX' title='Eagle Pharmaceuticals, Inc.'>EGRX</a> <font color=\"red\">-2.88%</font>. <a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a> <font color=\"red\">-2.86%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476360\" data-linked=\"OGI, FRAC, NBR and DDD among after hour movers\" data-tweet=\"$OGI $MR $NEX - OGI, FRAC, NBR and DDD among after hour movers https://seekingalpha.com/news/3476360-ogi-frac-nbr-and-ddd-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476360-ogi-frac-nbr-and-ddd-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476326\" data-ts=\"1562617482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZRX\" target=\"_blank\">AZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476326-azurrx-initiates-new-mid-stage-study-of-ms1819-sd-in-cystic-fibrosis-shares-up-12-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AzurRx initiates new mid-stage study of MS1819-SD in cystic fibrosis; shares up 12% after hours</a></h4><ul><li>Thinly traded nano cap AzurRx BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/AZRX' title='AzurRx BioPharma, Inc.'>AZRX</a>) is up <font color=\"green\">12% </font>after hours on light volume in response to the launch of a <a href=\"https://seekingalpha.com/pr/17564871-azurrx-biopharma-announces-initiation-phase-2-clinical-study-ms1819-sd-combination-standard\" target=\"_blank\">Phase 2 clinical trial</a> evaluating MS1819-SD, combined with standard porcine enzyme replacement therapy &#40;PERT&#41;, in cystic fibrosis patients with severe exocrine pancreatic insufficiency who continue to experience clinical symptoms of fat malabsorption despite maximum PERT therapy. Preliminary data should be available in early 2020. The trial should be completed later that year.</li><li>Another Phase 2, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03746483?lead=azurrx+biopharma&amp;phase=1&amp;rank=1\" target=\"_blank\">OPTION</a>, assessing MS1819-SD in a head-to-head comparison with PERT, is ongoing with topline data expected in August/September.</li><li>Management will host a conference call at 4:30 pm ET to discuss the study and provide an R&amp;D update.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476326\" data-linked=\"AzurRx initiates new mid-stage study of MS1819-SD in cystic fibrosis; shares up 12% after hours\" data-tweet=\"$AZRX - AzurRx initiates new mid-stage study of MS1819-SD in cystic fibrosis; shares up 12% after hours https://seekingalpha.com/news/3476326-azurrx-initiates-new-mid-stage-study-of-ms1819-sd-in-cystic-fibrosis-shares-up-12-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3476326-azurrx-initiates-new-mid-stage-study-of-ms1819-sd-in-cystic-fibrosis-shares-up-12-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476320\" data-ts=\"1562616988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMFC\" target=\"_blank\">NMFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476320-new-mountain-finance-starts-capital-raise-sharesminus-1_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Mountain Finance starts capital raise; shares -1.4%</a></h4><ul><li>New Mountain Finance (NYSE:<a href='https://seekingalpha.com/symbol/NMFC' title='New Mountain Finance'>NMFC</a>) <font color=\"red\">slips 1.4% </font>in after-hours trading after <a href=\"https://seekingalpha.com/pr/17564907-new-mountain-finance-corporation-commences-offering-6000-000-shares-common-stock\" target=\"_blank\">starting a public offering </a>of 6M shares of its common stock.</li><li>Expects to grant a greenshoe option for up to an additional 900K shares.</li><li>The company intends to use the net proceeds from the offering primarily for new investments in portfolio companies in accordance with its investment objective and strategies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476320\" data-linked=\"New Mountain Finance starts capital raise; shares -1.4%\" data-tweet=\"$NMFC - New Mountain Finance starts capital raise; shares -1.4% https://seekingalpha.com/news/3476320-new-mountain-finance-starts-capital-raise-sharesminus-1_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3476320-new-mountain-finance-starts-capital-raise-sharesminus-1_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476308\" data-ts=\"1562616147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476308-bitcoins-back-over-12k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin&#39;s back over $12K</a></h4><ul><li>A late-June collapse brought Bitcoin (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) from above $13K to all the way below $10K, but it's been quietly rallying since, and a big jump in the past few minutes has the price back to $12.2K.</li><li>Some technicians think the move above $12K sets Bitcoin up <a href=\"https://www.coindesk.com/bitcoin-price-nears-12k-after-rising-500-in-minutes\" target=\"_blank\">to challenge the</a> recent high of $13.9K.</li><li>Bitcoin continues to outperform other cryptos like Ether (<a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>), Bitcoin Cash (<a href='https://seekingalpha.com/symbol/BCH-USD' title='Bitcoin Cash USD'>BCH-USD</a>), Litecoin (<a href='https://seekingalpha.com/symbol/LTC-USD' title='Litecoin USD'>LTC-USD</a>), and Ripple (<a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>).</li><li>The Grayscale Bitcoin Trust (<a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a> <font color=\"green\">+7.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476308\" data-linked=\"Bitcoin&#39;s back over $12K\" data-tweet=\"$GBTC $BTC-USD $ETH-USD - Bitcoin&#39;s back over $12K https://seekingalpha.com/news/3476308-bitcoins-back-over-12k?source=tweet\" data-url=\"https://seekingalpha.com/news/3476308-bitcoins-back-over-12k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476304\" data-ts=\"1562615194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNPOF\" target=\"_blank\">CNPOF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476304-canopy-rivers-up-10-on-terrascend-cannabis-oil-license\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Rivers up 10% on TerrAscend cannabis oil license</a></h4><ul><li>Thinly traded micro cap Canopy Rivers (<a href='https://seekingalpha.com/symbol/CNPOF' title='Canopy Rivers Inc.'>OTCPK:CNPOF</a> <font color=\"green\">+9.7%</font>) is up on more than double normal volume, albeit on turnover of only 275K shares, in response to Health Canada issuing a <a href=\"https://seekingalpha.com/pr/17564833-canopy-rivers-portfolio-company-terrascend-receives-cannabis-oil-sales-licence-canada\" target=\"_blank\">license </a>to portfolio company TerrAscend Corp. (<a href='https://seekingalpha.com/symbol/TRSSF' title='TerrAscend Corp.'>OTCQX:TRSSF</a> <font color=\"red\">-2.4%</font>) for the sale of cannabis oils from its Mississauga, Ontario facility.</li><li>The oils will be available immediately via TerrAscend's medical marketplace <a href=\"https://solacehealth.com/\" target=\"_blank\">Solace Health</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476304\" data-linked=\"Canopy Rivers up 10% on TerrAscend cannabis oil license\" data-tweet=\"$CNPOF $TRSSF - Canopy Rivers up 10% on TerrAscend cannabis oil license https://seekingalpha.com/news/3476304-canopy-rivers-up-10-on-terrascend-cannabis-oil-license?source=tweet\" data-url=\"https://seekingalpha.com/news/3476304-canopy-rivers-up-10-on-terrascend-cannabis-oil-license\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476303\" data-ts=\"1562615026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERI\" target=\"_blank\">ERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476303-union-gaming-points-to-eldorados-synergy-success\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Gaming points to Eldorado&#39;s synergy success</a></h4><ul><li>Union Gaming lifts its price target on Eldorado Resorts (<a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a> <font color='red'>-1.6%</font>) to $70 from $60 to factor in higher estimates.</li><li>\"We remain confident not only that ERI will meet its $500m synergy target, but exceed it,\" updates analyst John DeCree.</li><li>DeCree and team observe that Eldorado has a strong track record of topping its synergy targets.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476303\" data-linked=\"Union Gaming points to Eldorado&#39;s synergy success\" data-tweet=\"$ERI - Union Gaming points to Eldorado&#39;s synergy success https://seekingalpha.com/news/3476303-union-gaming-points-to-eldorados-synergy-success?source=tweet\" data-url=\"https://seekingalpha.com/news/3476303-union-gaming-points-to-eldorados-synergy-success\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476297\" data-ts=\"1562613030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VHC\" target=\"_blank\">VHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476297-virnetx-claims-patent-decision-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VirnetX claims patent decision win</a></h4><ul> <li>VirnetX (<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corp'>VHC</a> <font color='green'>+2.6%</font>) says the U.S. Court of Appeals for the Federal Circuit issued two favorable opinions for the company today.</li><li>The company says the decisions vacated and remanded two decisions by the USPTO, agreeing with VirnetX that the board abused its discretion in denying it the opportunity to file a motion for additional discovery as to real party-in-interest issues and that many of the Board's positions as to the prior art lacked substantial evidence.</li> <li>\"We are extremely pleased with the Federal Court's decision which vindicates many of VirnetX's arguments about the Patent Board's decisions,\" says VirnetX CEO Kendall Larsen.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17564754-virnetx-wins-patent-appeal-apple-case-us-court-appeals-federal-circuit\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3476297\" data-linked=\"VirnetX claims patent decision win\" data-tweet=\"$VHC - VirnetX claims patent decision win https://seekingalpha.com/news/3476297-virnetx-claims-patent-decision-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3476297-virnetx-claims-patent-decision-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476296\" data-ts=\"1562612937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476296-microcaps-top-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps top tech movers</a></h4><ul><li><strong>Gainers</strong>: Ideanomics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDEX' title='Ideanomics, Inc.'>IDEX</a>) <font color=\"green\">+13%</font>. TuanChe (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"green\">+11%</font>. Lantronix (NASDAQ:<a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a>) <font color=\"green\">+11%</font>. Internap (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Corporation'>INAP</a>) <font color=\"green\">+10%</font>. Luokung Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/LKCO' title='Luokung Technology Corp.'>LKCO</a>) <font color=\"green\">+10%</font>.</li> <li><strong>Losers</strong>: Jiayin Group (NASDAQ:<a href='https://seekingalpha.com/symbol/JFIN' title='Jiayin Group Inc.'>JFIN</a>) <font color=\"red\">-14%</font>. Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings, Inc.'>AWSM</a>) <font color=\"red\">-11%</font>. MicroStrategy (NASDAQ:<a href='https://seekingalpha.com/symbol/MSTR' title='MicroStrategy Incorporated'>MSTR</a>) <font color=\"red\">-10%</font>. Fang Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Limited'>SFUN</a>) <font color=\"red\">-9%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware, Inc.'>PHUN</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476296\" data-linked=\"Microcaps top tech movers\" data-tweet=\"$IDEX $TC $LTRX - Microcaps top tech movers https://seekingalpha.com/news/3476296-microcaps-top-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476296-microcaps-top-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476290\" data-ts=\"1562611636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAYZF\" target=\"_blank\">BAYZF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476290-bayer-cut-fitch-outlook-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bayer cut by Fitch; outlook negative</a></h4><ul><li>Fitch Ratings <a href=\"https://www.fitchratings.com/site/pr/10081587\" target=\"_blank\">downgrades</a> Bayer AG's (<a href='https://seekingalpha.com/symbol/BAYZF' title='Bayer Aktiengesellschaft'>OTCPK:BAYZF</a> <font color='red'>-3.3%</font>) long-term issuer default rating to BBB+ from A-; outlook negative.</li><li>Short-term IDR of FS affirmed.</li><li>Fitch says the crop science division has deteriorated during the past year due to the debate surrounding glyphosate (branded as Roundup), and sees risk that the company's deleveraging from the post-acquisition peak of  2018 may be delayed after 2020.</li><li>Negative outlook reflects an increased risk of potentially material payouts in connection to the glyphosate litigation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3475590-u-s-judge-slash-roundup-jury-verdict\" target=\"_blank\">U.S. judge to slash Roundup jury verdict</a> (July 3)</li><li>Related ticker: <a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3476290\" data-linked=\"Bayer cut by Fitch; outlook negative\" data-tweet=\"$BAYZF $BAYZF $BAYRY - Bayer cut by Fitch; outlook negative https://seekingalpha.com/news/3476290-bayer-cut-fitch-outlook-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3476290-bayer-cut-fitch-outlook-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476280\" data-ts=\"1562609220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZO\" target=\"_blank\">AZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476280-new-high-for-autozone-buy-signs-all-around\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New high for AutoZone with buy signs all around</a></h4><ul> <li>AutoZone (NYSE:<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc.'>AZO</a>) is <font color=\"green\">up another 1.1%</font> and carved out a new high of $1,142.91 earlier in the session.</li> <li>The company continues to fall on to the radar of investors of looking for stocks in the retail sector with growing comparable sales and expanding margins, while also being insulated somewhat from Amazon and tariffs. On Seeking Alpha, the <a href=\"https://seekingalpha.com/symbol/AZO/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> on AutoZone is flashing Very Bullish and the SA Authors' rating is Bullish.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476280\" data-linked=\"New high for AutoZone with buy signs all around\" data-tweet=\"$AZO - New high for AutoZone with buy signs all around https://seekingalpha.com/news/3476280-new-high-for-autozone-buy-signs-all-around?source=tweet\" data-url=\"https://seekingalpha.com/news/3476280-new-high-for-autozone-buy-signs-all-around\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476275\" data-ts=\"1562607264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADVM\" target=\"_blank\">ADVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476275-adverum-up-10-ahead-of-advmminus-022-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adverum up 10% ahead of ADVM-022 data readout</a></h4><ul><li>Adverum Biotechnologies (<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a> <font color=\"green\">+10.4%</font>) is up on more than double normal volume in apparent anticipation of positive 24-week data from its Phase 1 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03748784?spons=adverum&amp;rank=3\" target=\"_blank\">OPTIC </a>study evaluating gene therapy ADVM-022 in wet AMD. Earlier today, it <a href=\"https://seekingalpha.com/pr/17564099-adverum-biotechnologies-present-data-upcoming-conferences\" target=\"_blank\">announced</a> that interim results will be presented at the Annual Retina Society Meeting in London on September 12.</li><li>CEO Leone Patterson says, \u201cWe have shared previously that we have seen a robust preliminary anatomical response, with no serious adverse events, from the first cohort of patients in the OPTIC Phase 1 clinical trial. We are excited to share the 24-week data from the first cohort of patients with wet AMD treated with a single intravitreal injection of our novel gene therapy ADVM-022.\u201d</li></ul><div class=\"tiny-share-widget\" data-id=\"3476275\" data-linked=\"Adverum up 10% ahead of ADVM-022 data readout\" data-tweet=\"$ADVM - Adverum up 10% ahead of ADVM-022 data readout https://seekingalpha.com/news/3476275-adverum-up-10-ahead-of-advmminus-022-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3476275-adverum-up-10-ahead-of-advmminus-022-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476274\" data-ts=\"1562607101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476274-juniper-networksminus-3_4-citi-sees-outrun-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juniper Networks -3.4% as Citi sees outrun expectations</a></h4><ul>   <li>Juniper Networks (NYSE:<a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks, Inc.'>JNPR</a>) is among the drags on a downcast tech market today, <font color=\"red\">dropping 3.4%</font> and touching its lowest point in over a month, as Citi downgrades to Sell from Neutral.</li>    <li>Expectations for the second half are \"too lofty,\" Jim Suva says, amid share gains from rivals Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) and Cisco (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) that are set to come out of Juniper's market share.</li>    <li>He's trimmed his price target to $24 from $28, now implying 9% downside.</li>    <li>Meanwhile, other sell-siders rate the stock <a href=\"https://seekingalpha.com/symbol/JNPR/ratings/sell-side-ratings\" target=\"_blank\">Hold on average</a>, <a href=\"https://seekingalpha.com/symbol/JNPR/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are similarly Neutral</a>, and the stock has a <a href=\"https://seekingalpha.com/symbol/JNPR/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476274\" data-linked=\"Juniper Networks -3.4% as Citi sees outrun expectations\" data-tweet=\"$JNPR $ANET $CSCO - Juniper Networks -3.4% as Citi sees outrun expectations https://seekingalpha.com/news/3476274-juniper-networksminus-3_4-citi-sees-outrun-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3476274-juniper-networksminus-3_4-citi-sees-outrun-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476272\" data-ts=\"1562606326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WW\" target=\"_blank\">WW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476272-volatility-alert-on-weight-watchers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatility alert on Weight Watchers</a></h4><ul> <li>Weight Watchers (NASDAQ:<a href='https://seekingalpha.com/symbol/WW' title='Weight Watchers International, Inc.'>WW</a>) is <font color=\"green\">up 8.65% </font>on a strong move that coincides with a pickup in options activity.</li> <li>Bloomberg reports options activity is 20X normal activity, with most of the action on calls dated July 12.</li> <li>Short interest on Weight Watchers has moved lower recently, but is still represents over 15% of total float.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476272\" data-linked=\"Volatility alert on Weight Watchers\" data-tweet=\"$WW - Volatility alert on Weight Watchers https://seekingalpha.com/news/3476272-volatility-alert-on-weight-watchers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476272-volatility-alert-on-weight-watchers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476271\" data-ts=\"1562606001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476271-nike-looks-to-capitalize-on-world-cup-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike looks to capitalize on World Cup buzz</a></h4><ul> <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='NIKE, Inc.'>NKE</a>) says a special version of the jersey of the U.S. Women's Soccer team that includes all four World Cup stars has already sold out on its site for many women's, men's and kids sizes.</li> <li>The athletic apparel giant was well-prepared for the U.S. win in the final, airing a special soccer-themed advertisement almost immediately on Fox Sports. The ad has also been viewed more than 20M times on <a href=\"https://twitter.com/Nike/status/1147912201652469760\" target=\"_blank\">Twitter</a>.</li> <li>Nike is hoping World Cup product sales will be enough to help the company repeat its strong performance in North American last quarter (<a href=\"https://seekingalpha.com/pr/17558602-nike-inc-reports-fiscal-2019-fourth-quarter-full-year-results\" target=\"_blank\">+7%</a> Y/Y) when it topped analyst expectations.</li> <li>Shares of Nike are <font color=\"green\">up 1.22%</font> on the day to sit at a two-month high.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476271\" data-linked=\"Nike looks to capitalize on World Cup buzz\" data-tweet=\"$NKE - Nike looks to capitalize on World Cup buzz https://seekingalpha.com/news/3476271-nike-looks-to-capitalize-on-world-cup-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3476271-nike-looks-to-capitalize-on-world-cup-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476268\" data-ts=\"1562605363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476268-nuverra-environmental-solutions-leads-industrial-gainers-aqua-metals-and-limbach-holdings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuverra Environmental Solutions leads industrial gainers; Aqua Metals and Limbach Holdings among losers</a></h4><ul><li><b>Gainers: </b>Nuverra Environmental Solutions (NYSEMKT:<a href='https://seekingalpha.com/symbol/NES' title='Nuverra Environmental Solutions, Inc.'>NES</a>) <font color=\"green\">+35%</font>. Orion Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"green\">+14%</font>. The New Home Company (NYSE:<a href='https://seekingalpha.com/symbol/NWHM' title='The New Home Company Inc.'>NWHM</a>) <font color=\"green\">+8%</font>. AZZ (NYSE:<a href='https://seekingalpha.com/symbol/AZZ' title='AZZ Inc.'>AZZ</a>) <font color=\"green\">+7%</font>. Mayville Engineering Company (NYSE:<a href='https://seekingalpha.com/symbol/MEC' title='Mayville Engineering Company, Inc.'>MEC</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Aqua Metals (NASDAQ:<a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals, Inc.'>AQMS</a>) <font color=\"red\">-5%</font>. Limbach Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMB' title='Limbach Holdings, Inc.'>LMB</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476268\" data-linked=\"Nuverra Environmental Solutions leads industrial gainers; Aqua Metals and Limbach Holdings among losers\" data-tweet=\"$NES $ORN $NWHM - Nuverra Environmental Solutions leads industrial gainers; Aqua Metals and Limbach Holdings among losers https://seekingalpha.com/news/3476268-nuverra-environmental-solutions-leads-industrial-gainers-aqua-metals-and-limbach-holdings?source=tweet\" data-url=\"https://seekingalpha.com/news/3476268-nuverra-environmental-solutions-leads-industrial-gainers-aqua-metals-and-limbach-holdings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476267\" data-ts=\"1562605291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476267-yintech-investment-holdings-only-financial-gainer-yirendai-and-puyi-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yintech Investment Holdings the only financial gainer, Yirendai and Puyi among losers</a></h4><ul><li><b>Gainers:</b> Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers:</b> Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">-18%</font>. Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-14%</font>. Puyi (NASDAQ:<a href='https://seekingalpha.com/symbol/PUYI' title='Puyi Inc.'>PUYI</a>) <font color=\"red\">-11%</font>. Yirendai (NYSE:<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai Ltd.'>YRD</a>) <font color=\"red\">-10%</font>. LendingClub (NYSE:<a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476267\" data-linked=\"Yintech Investment Holdings the only financial gainer, Yirendai and Puyi among losers\" data-tweet=\"$YIN $NOAH $AIHS - Yintech Investment Holdings the only financial gainer, Yirendai and Puyi among losers https://seekingalpha.com/news/3476267-yintech-investment-holdings-only-financial-gainer-yirendai-and-puyi-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476267-yintech-investment-holdings-only-financial-gainer-yirendai-and-puyi-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476265\" data-ts=\"1562604798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIB\" target=\"_blank\">BIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476265-biotechs-and-biopharmas-under-pressure-ahead-of-trump-order-on-drug-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs and biopharmas under pressure ahead of Trump order on drug prices</a></h4><ul><li>Biopharma and biotech players are mostly in the red (again) ahead of an <a href=\"http://www.pharmafile.com/news/524235/trump-says-executive-order-will-ensure-us-will-pay-lowest-prices-world-drugs\" target=\"_blank\">expected executive order</a> from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a \"favored nation\" clause that will be the basis for Medicare reimbursement, i.e., the reimbursement rates will match those in the country paying the lowest prices instead of an index of drug prices from around the world.</li><li>Pushback from manufacturers should be substantial. The fireworks will, no doubt, be good theatre.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a>, <a href='https://seekingalpha.com/symbol/GRX' title='The Gabelli Healthcare & Wellness Rx Trust'>GRX</a>, <a href='https://seekingalpha.com/symbol/THW' title='Tekla World Healthcare Fund'>THW</a>, <a href='https://seekingalpha.com/symbol/BME' title='BlackRock Health Sciences Trust'>BME</a>, <a href='https://seekingalpha.com/symbol/BIS' title='ProShares UltraShort Nasdaq Biotechnology ETF'>BIS</a>, <a href='https://seekingalpha.com/symbol/IXJ' title='iShares Global Healthcare ETF'>IXJ</a>, <a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a>, <a href='https://seekingalpha.com/symbol/CHNA' title='The Loncar China BioPharma ETF'>CHNA</a>, <a href='https://seekingalpha.com/symbol/IDNA' title='iShares Genomics Immunology and Healthcare ETF'>IDNA</a>, <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a></li><li>Selected tickers: Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"red\">-2.5%</font>), Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-2.1%</font>), Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"red\">-2.5%</font>), Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"red\">-1.7%</font>), Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"red\">-2.2%</font>), Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color=\"red\">-1.4%</font>), Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"red\">-1.1%</font>), Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"red\">-1.7%</font>), Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"green\">+0.3%</font>), Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a> <font color=\"red\">-0.7%</font>), AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"red\">-2.5%</font>), Bausch Health Companies (<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color=\"red\">-2%</font>), Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"red\">-2.3%</font>), AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"red\">-0.5%</font>), GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a> <font color=\"red\">-0.5%</font>), Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"green\">+0.1%</font>), Takeda (<a href='https://seekingalpha.com/symbol/TAK' title='Takeda Pharmaceutical Company Limited'>TAK</a> <font color=\"red\">-0.6%</font>), Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"red\">-1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476265\" data-linked=\"Biotechs and biopharmas under pressure ahead of Trump order on drug prices\" data-tweet=\"$BIB $GRX $THW - Biotechs and biopharmas under pressure ahead of Trump order on drug prices https://seekingalpha.com/news/3476265-biotechs-and-biopharmas-under-pressure-ahead-of-trump-order-on-drug-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3476265-biotechs-and-biopharmas-under-pressure-ahead-of-trump-order-on-drug-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>202&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476257\" data-ts=\"1562603635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476257-gtt-buying-kpn-international-for-50m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GTT buying KPN International for \u20ac50M</a></h4><ul>   <li>GTT Communications (<a href=\"http://seekingalpha.com/symbol/GTT\" target=\"_blank\">GTT</a> <font color=\"red\">-4%</font>) has an <a href=\"https://www.totaltele.com/view.aspx?ID=503354\" target=\"_blank\">agreement</a> to take over Royal KPN's (<a href=\"http://seekingalpha.com/symbol/KKPNY\" target=\"_blank\">KKPNY</a> <font color=\"red\">-1.2%</font>) international network, for \u20ac50M.</li>    <li>That covers points of presence in 21 countries as well as the international fiber assets. KPN will enter a master services agreement to ensure service continuity.</li>    <li>It allows KPN to unload noncore assets while GTT can scale up across mainland Europe.</li>    <li>The deal will proceed on a cash-free debt-free basis and is expected to wrap in Q3.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476257\" data-linked=\"GTT buying KPN International for \u20ac50M\" data-tweet=\"$GTT $KKPNY - GTT buying KPN International for \u20ac50M https://seekingalpha.com/news/3476257-gtt-buying-kpn-international-for-50m?source=tweet\" data-url=\"https://seekingalpha.com/news/3476257-gtt-buying-kpn-international-for-50m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476255\" data-ts=\"1562603545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476255-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers: </strong>Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"green\">+68%</font>. Nuverra Environmental Solutions (NYSEMKT:<a href='https://seekingalpha.com/symbol/NES' title='Nuverra Environmental Solutions, Inc.'>NES</a>) <font color=\"green\">+40%</font>. Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"green\">+31%</font>. Oasmia Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical AB &#40;publ&#41;'>OASM</a>) <font color=\"green\">+24%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+15%</font>. BIOLASE (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOL' title='BIOLASE, Inc.'>BIOL</a>) <font color=\"green\">+14%</font>. Sol-Gel Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SLGL' title='Sol-Gel Technologies Ltd.'>SLGL</a>) <font color=\"green\">+13%. </font>Orion Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"green\">+13%</font>. Internap Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Corporation'>INAP</a>) <font color=\"green\">+11%</font>. Wah Fu Education Group Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/WAFU' title='Wah Fu Education Group Limited'>WAFU</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"red\">-22%</font>. CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) <font color=\"red\">-21%</font>. Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-21%</font>. Coherus BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences, Inc.'>CHRS</a>) <font color=\"red\">-18%</font>. Noah Holdings Limited (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">-18%</font>. Harvard Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/HBIO' title='Harvard Bioscience, Inc.'>HBIO</a>) <font color=\"red\">-16%</font>. Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) <font color=\"red\">-14%</font>. Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-14%</font>. Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"red\">-14%</font>. Corvus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CRVS' title='Corvus Pharmaceuticals, Inc.'>CRVS</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476255\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$TRNX $NES $SOLY - Microcaps mostly among midday movers https://seekingalpha.com/news/3476255-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476255-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476250\" data-ts=\"1562602454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLGL\" target=\"_blank\">SLGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476250-sol-gel-up-13-positive-epsolay-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sol-Gel up 13% positive Epsolay data</a></h4><ul><li>Ultra-thinly traded micro cap Sol-Gel Technologies (<a href='https://seekingalpha.com/symbol/SLGL' title='Sol-Gel Technologies Ltd.'>SLGL</a> <font color=\"green\">+13.1%</font>) is up on almost a 19x surge in volume, albeit on turnover of only 267K shares, in response to <a href=\"https://seekingalpha.com/pr/17564050-sol-gel-announces-positive-top-line-results-epsolay-phase-3-program-papulopustular-rosacea\" target=\"_blank\">positive results</a> from two Phase 3 clinical trials, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03448939?term=sol-gel+technologies&amp;rank=4\" target=\"_blank\">SGT 54-01</a> and <a href=\"https://clinicaltrials.gov/ct2/show/NCT03564119?term=sol-gel+technologies&amp;rank=3\" target=\"_blank\">SGT 54-02</a>, evaluating Epsolay microencapsulated benzoyl peroxide cream, 5% for the treatment of an acne-like skin disorder called papulopustular rosacea.</li><li>Both studies achieved the co-primary efficacy endpoints, the proportion of patients achieving clear or almost clear skin at week 12 and the absolute change in lesion count at week 12.</li><li>Other updates: Preliminary Q2 revenue will be ~$7M from sales of its generic acyclovir cream by partner Perrigo. Phase 3 data on TWIN in acne vulgaris should be available in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476250\" data-linked=\"Sol-Gel up 13% positive Epsolay data\" data-tweet=\"$SLGL - Sol-Gel up 13% positive Epsolay data https://seekingalpha.com/news/3476250-sol-gel-up-13-positive-epsolay-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3476250-sol-gel-up-13-positive-epsolay-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476249\" data-ts=\"1562602386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LTRX\" target=\"_blank\">LTRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476249-lantronix-acquires-maestro-and-falcom-holdings-for-4_9m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lantronix acquires Maestro and FALCOM Holdings for $4.9M</a></h4><ul><li>Lantronix (<a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color=\"green\">+5.2%</font>) <a href=\"https://seekingalpha.com/pr/17564192-lantronix-acquires-maestro-falcom-holdings-limited\" target=\"_blank\">announces</a> the acquisition of all of the business of Maestro &amp; FALCOM Holdings Limited, a leading supplier of wireless IoT product.</li><li>Lantronix acquired 100% of the issued share capital of each of its operating subsidiaries, Maestro Wireless Solutions Limited and Fargo Telecom Asia Limited for $4.9M in cash.</li><li>\"This acquisition allows Lantronix to offer \u2018best in class\u2019 products in wired Ethernet, Wi-Fi, LoRa/LPWAN, and now in cellular environments as well. This transaction represents Lantronix\u2019s commitment to deliver incremental growth and shareholder value through acquisition,\u201d stated Paul Pickle, president, and CEO of Lantronix.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476249\" data-linked=\"Lantronix acquires Maestro and FALCOM Holdings for $4.9M\" data-tweet=\"$LTRX - Lantronix acquires Maestro and FALCOM Holdings for $4.9M https://seekingalpha.com/news/3476249-lantronix-acquires-maestro-and-falcom-holdings-for-4_9m?source=tweet\" data-url=\"https://seekingalpha.com/news/3476249-lantronix-acquires-maestro-and-falcom-holdings-for-4_9m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476246\" data-ts=\"1562601660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476246-edgewell-personal-care-only-consumer-gainer-china-xd-plastics-company-only-loser\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edgewell Personal Care only consumer gainer; China XD Plastics Company only loser</a></h4><ul><li><b>Gainers: </b>Edgewell Personal Care (NYSE:<a href='https://seekingalpha.com/symbol/EPC' title='Edgewell Personal Care Company'>EPC</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>China XD Plastics Company (NASDAQ:<a href='https://seekingalpha.com/symbol/CXDC' title='China XD Plastics Company Limited'>CXDC</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476246\" data-linked=\"Edgewell Personal Care only consumer gainer; China XD Plastics Company only loser\" data-tweet=\"$EPC $CXDC - Edgewell Personal Care only consumer gainer; China XD Plastics Company only loser https://seekingalpha.com/news/3476246-edgewell-personal-care-only-consumer-gainer-china-xd-plastics-company-only-loser?source=tweet\" data-url=\"https://seekingalpha.com/news/3476246-edgewell-personal-care-only-consumer-gainer-china-xd-plastics-company-only-loser\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476236\" data-ts=\"1562600340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBIO\" target=\"_blank\">HBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476236-harvard-bio-off-15-on-ceo-exit-janney-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harvard Bio off 15% on CEO exit, Janney downgrade</a></h4><ul><li>Thinly traded nano cap Harvard Bioscience (<a href='https://seekingalpha.com/symbol/HBIO' title='Harvard Bioscience, Inc.'>HBIO</a> <font color=\"red\">-14.7%</font>) slumps on more than a 4x surge in volume following a downgrade to Neutral with a $2 (23% upside) price target at Janney Montgomery following the <a href=\"https://www.sec.gov/Archives/edgar/data/1123494/000117184319004441/f8k_070819.htm\" target=\"_blank\">departure</a> of President &amp; CEO Jeffrey Duchemin.</li><li>Director James Green has taken over from Mr. Duchemin.</li><li>Quant rating is <a href=\"https://seekingalpha.com/symbol/HBIO/ratings/quant-ratings\" target=\"_blank\">Neutral </a>while the Sell Side rating is <a href=\"https://seekingalpha.com/symbol/HBIO/ratings/sell-side-ratings\" target=\"_blank\">Buy</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476236\" data-linked=\"Harvard Bio off 15% on CEO exit, Janney downgrade\" data-tweet=\"$HBIO - Harvard Bio off 15% on CEO exit, Janney downgrade https://seekingalpha.com/news/3476236-harvard-bio-off-15-on-ceo-exit-janney-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3476236-harvard-bio-off-15-on-ceo-exit-janney-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476234\" data-ts=\"1562599720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLY\" target=\"_blank\">SOLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476234-soliton-up-25-ahead-of-shockwave-data-in-cellulite\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soliton up 25% ahead of shockwave data in cellulite</a></h4><ul><li>Soliton (<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a> <font color=\"green\">+25%</font>) is up on 34% higher volume in apparent response to its <a href=\"https://seekingalpha.com/pr/17564130-soliton-announce-cellulite-trial-data-26-week-period-july-15-2019\" target=\"_blank\">announcement</a> that will will release cumulative 26-week patient data from its proof-of-concept study evaluating its acoustic shockwave device for the potential treatment of moderate-to-severe cellulite on Monday, July 15.</li><li>According to President and co-founder Chris Capelli, the initial results are promising.</li><li>A pivotal trial should launch later this summer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476234\" data-linked=\"Soliton up 25% ahead of shockwave data in cellulite\" data-tweet=\"$SOLY - Soliton up 25% ahead of shockwave data in cellulite https://seekingalpha.com/news/3476234-soliton-up-25-ahead-of-shockwave-data-in-cellulite?source=tweet\" data-url=\"https://seekingalpha.com/news/3476234-soliton-up-25-ahead-of-shockwave-data-in-cellulite\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476228\" data-ts=\"1562598382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476228-oasmia-pharmaceutical-and-xenetic-biosciences-among-healthcare-gainers-intra-cellular\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasmia Pharmaceutical and Xenetic Biosciences among healthcare gainers; Intra-Cellular Therapies leads the losers</a></h4><ul><li><b>Gainers: </b>Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"green\">+26%</font>. Oasmia Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical AB &#40;publ&#41;'>OASM</a>) <font color=\"green\">+24%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+13%</font>. Sol-Gel Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SLGL' title='Sol-Gel Technologies Ltd.'>SLGL</a>) <font color=\"green\">+13%</font>. Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"red\">-24%</font>. CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) <font color=\"red\">-19%</font>. Coherus BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences, Inc.'>CHRS</a>) <font color=\"red\">-16%</font>. Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"red\">-12%</font>. Melinta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNT' title='Melinta Therapeutics, Inc.'>MLNT</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476228\" data-linked=\"Oasmia Pharmaceutical and Xenetic Biosciences among healthcare gainers; Intra-Cellular Therapies leads the losers\" data-tweet=\"$SOLY $OASM $XBIO - Oasmia Pharmaceutical and Xenetic Biosciences among healthcare gainers; Intra-Cellular Therapies leads the losers https://seekingalpha.com/news/3476228-oasmia-pharmaceutical-and-xenetic-biosciences-among-healthcare-gainers-intra-cellular?source=tweet\" data-url=\"https://seekingalpha.com/news/3476228-oasmia-pharmaceutical-and-xenetic-biosciences-among-healthcare-gainers-intra-cellular\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476223\" data-ts=\"1562597639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476223-bellicum-up-3-on-positive-rivo-cell-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellicum up 3% on positive rivo-cell data</a></h4><ul><li>Nano cap Bellicum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals, Inc.'>BLCM</a> <font color=\"green\">+2.8%</font>) perks up on below-average volume in response to <a href=\"https://seekingalpha.com/pr/17564212-bellicum-pharmaceuticals-announces-rivo-cel-achieves-primary-endpoint-pediatric\" target=\"_blank\">positive results</a> from a European <a href=\"https://clinicaltrials.gov/ct2/show/NCT02065869?term=nct02065869&amp;rank=1\" target=\"_blank\">registration trial</a> supporting its Rivo-cel (rivogenlecleucel) allogeneic T cell product in pediatric patients with malignant or non-malignant blood cell disorders who are receiving a blood stem cell transplant depleted of T cell receptor alpha and beta cells that come from a partially matched family donor.</li><li>The data showed that adding Rivo-cel to stem cell transplants in patients lacking a matched donor produced comparable outcomes to HLA-matched unrelated donor transplants. Specifically, the rate of event-free survival &#40;EFS&#41; at day 180 in the treatment group was 90.9% which was non-inferior (no worse than) to 89.9% in patients receiving a hematopoietic stem cell transplant from an HLA-matched unrelated donor, the primary endpoint.</li><li>The company says Rivo-cel should be an attractive treatment option for the 20 - 25% of stem cell transplant patients who lack an HLA-matched donor [Human Leukocyte Antigen &#40;HLA&#41; <a href=\"https://www.seattlecca.org/treatments/bone-marrow-transplant/bone-marrow-transplant-facts/HLA-typing\" target=\"_blank\">matching</a> greatly improves the probability of a successful transplant while reducing the risk of complications like graft-versus-host disease].</li><li>The company is seeking a strategic partner for Rivo-cel's potential commercial launch in Europe.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476223\" data-linked=\"Bellicum up 3% on positive rivo-cell data\" data-tweet=\"$BLCM - Bellicum up 3% on positive rivo-cell data https://seekingalpha.com/news/3476223-bellicum-up-3-on-positive-rivo-cell-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3476223-bellicum-up-3-on-positive-rivo-cell-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476222\" data-ts=\"1562597278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTWK\" target=\"_blank\">NTWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476222-netsol-technologies-acquires-remaining-stake-in-virtual-lease-services\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NETSOL Technologies acquires remaining stake in Virtual Lease Services</a></h4><ul><li>NETSOL Technologies (<a href='https://seekingalpha.com/symbol/NTWK' title='NetSol Technologies, Inc.'>NTWK</a> <font color=\"red\">-1.8%</font>) <a href=\"https://seekingalpha.com/pr/17564185-netsol-technologies-acquires-remaining-stake-virtual-lease-services-becomes-outright-owner\" target=\"_blank\">announced</a> it has acquired the remaining 49% stake of Virtual Lease Services, a UK-based portfolio and risk management servicing partner for business and consumer finance providers.</li><li>NETSOL had acquired a 51% majority stake in VLS through a joint venture partnership with Investec in 2011.</li><li>In the past three years, VLS has recorded a 3-year compound annual growth rate north of 20%, and has been consistently and increasingly profitable over that period.</li><li>\u201cVLS is a highly complementary business to NETSOL\u2019s core competencies and has substantially improved its financial profile over the past several years since our initial strategic investment,\u201d stated Najeeb Ghauri, Co-Founder, Chairman and CEO, NETSOL.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476222\" data-linked=\"NETSOL Technologies acquires remaining stake in Virtual Lease Services\" data-tweet=\"$NTWK - NETSOL Technologies acquires remaining stake in Virtual Lease Services https://seekingalpha.com/news/3476222-netsol-technologies-acquires-remaining-stake-in-virtual-lease-services?source=tweet\" data-url=\"https://seekingalpha.com/news/3476222-netsol-technologies-acquires-remaining-stake-in-virtual-lease-services\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476221\" data-ts=\"1562596644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476221-edgewell-personal-careplus-5-after-suntrust-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edgewell Personal Care +5% after SunTrust boost</a></h4><ul> <li>SunTrust lifts Edgewell Personal Care (<a href='https://seekingalpha.com/symbol/EPC' title='Edgewell Personal Care Company'>EPC</a> <font color=\"green\">+5.3%</font>) to a Buy rating from Hold and takes its price target to $40.</li> <li>The firm warms up to Edgewell's deal to acquire Harry's and sees enough near-term catalysts to prompt the upgrade.</li> <li>Shares of Edgewell still trade on the low end of their 52-week range of $26.36 to $59.16.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476221\" data-linked=\"Edgewell Personal Care +5% after SunTrust boost\" data-tweet=\"$EPC - Edgewell Personal Care +5% after SunTrust boost https://seekingalpha.com/news/3476221-edgewell-personal-careplus-5-after-suntrust-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3476221-edgewell-personal-careplus-5-after-suntrust-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476218\" data-ts=\"1562596002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIW\" target=\"_blank\">ACIW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476218-aci-worldwideminus-2-after-valuation-eyed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ACI Worldwide -2% after valuation eyed</a></h4><ul> <li>ACI Worldwide (<a href='https://seekingalpha.com/symbol/ACIW' title='ACI Worldwide, Inc.'>ACIW</a> <font color='red'>-2.5%</font>) is lower on the day after Off Wall Street <a href=\"https://www.streetinsider.com/Analyst+Comments/ACI+Worldwide+%28ACIW%29+Initiated+as+Short+at+Off+Wall+Street/15681623.html\" target=\"_blank\">reportedly</a> issues a short recommendation on the tech stock.</li> <li>Off Wall Street is said to see \"aggressive valuation\" by the market on ACI.</li><li>The <a href=\"https://seekingalpha.com/symbol/ACIW/ratings/quant-ratings\" target=\"_blank\">Seeking Alpha Quant Rating</a> on ACI Worldwide is Bullish as the A+ grade on growth overrides the D+ grade on value.</li><li>Shares of ACI Worldwide are up 23% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476218\" data-linked=\"ACI Worldwide -2% after valuation eyed\" data-tweet=\"$ACIW - ACI Worldwide -2% after valuation eyed https://seekingalpha.com/news/3476218-aci-worldwideminus-2-after-valuation-eyed?source=tweet\" data-url=\"https://seekingalpha.com/news/3476218-aci-worldwideminus-2-after-valuation-eyed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476216\" data-ts=\"1562595780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GKOS\" target=\"_blank\">GKOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476216-ows-bearish-on-glaukos-shares-slip-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OWS bearish on Glaukos; shares slip 3%</a></h4><ul><li>Thinly traded Glaukos (<a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos Corporation'>GKOS</a> <font color=\"red\">-2.6%</font>) is down on below-average volume on the heels of a short recommendation at Off Wall Street &#40;OWS&#41; with a fair value target of $42.93 (44% downside risk).</li><li>OWS cites its bullish valuation that assumes much higher growth than is realistic since almost all high-volume U.S. cataract surgeons have been trained (heretofore, sales growth was driven by adding new doctors). It believes iStent sales growth should mirror the market's mid-single-digit growth.</li><li>Other factors supporting its bearish view include the end of the iStent sale bump from the recall of a competitive device in August 2018, the inability of the newer version of iStent to expand the market and a pipeline that is unlikely to contribute significant value until at least 2021.</li><li>Quant rating is <a href=\"https://seekingalpha.com/symbol/GKOS/ratings/quant-ratings\" target=\"_blank\">Bullish </a>and the Sell Side rating is <a href=\"https://seekingalpha.com/symbol/GKOS/ratings/sell-side-ratings\" target=\"_blank\">Outperform</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476216\" data-linked=\"OWS bearish on Glaukos; shares slip 3%\" data-tweet=\"$GKOS - OWS bearish on Glaukos; shares slip 3% https://seekingalpha.com/news/3476216-ows-bearish-on-glaukos-shares-slip-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3476216-ows-bearish-on-glaukos-shares-slip-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476215\" data-ts=\"1562595663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBE\" target=\"_blank\">KBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476215-large-cap-banks-cut-to-in-line-morgan-stanley\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Large-cap banks cut to in-line by Morgan Stanley</a></h4><ul><li>Morgan Stanley's Betsy Graseck <a href=\"https://www.bloomberg.com/news/articles/2019-07-08/morgan-stanley-downgrades-banks-taking-chips-off-the-table?utm_content=business&amp;utm_medium=social&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter\" target=\"_blank\">shifts her view</a> on large-cap banks to \"in-line\" from \"attractive,\" noting fewer positive catalysts ahead now that the Fed's stress tests are over.</li><li>State Street's SPDR S&amp;P Bank ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>)<font color=\"red\"> falls 0.6%</font>.</li><li>On top of that, the next six to 18 months \"look tougher\" as global GDP growth slows, inflation expectations dim, and the bond market pushes the Fed to cut interest rates in 2019 and 2020.</li><li>She<a href=\"https://seekingalpha.com/symbol/STT?s=stt\" target=\"_blank\"> cut State Street and Bank of New York Mellon</a> by two levels to underweight as they're more exposed to the yield curve.</li><li>Graseck writes that she likes companies that are \"liability sensitive/less exposed to rate cuts,\" such as American Express (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>) and Discover Financial (NYSE:<a href='https://seekingalpha.com/symbol/DFS' title='Discover Financial Services'>DFS</a>).</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>, <a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>, <a href='https://seekingalpha.com/symbol/GS' title='The Goldman Sachs Group, Inc.'>GS</a>, <a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>, <a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>, <a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Company'>WFC</a></li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3476215\" data-linked=\"Large-cap banks cut to in-line by Morgan Stanley\" data-tweet=\"$KBE $AXP $DFS - Large-cap banks cut to in-line by Morgan Stanley https://seekingalpha.com/news/3476215-large-cap-banks-cut-to-in-line-morgan-stanley?source=tweet\" data-url=\"https://seekingalpha.com/news/3476215-large-cap-banks-cut-to-in-line-morgan-stanley\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476214\" data-ts=\"1562595522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBLU\" target=\"_blank\">JBLU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476214-jetblue-gains-after-shaking-off-bear-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JetBlue gains after shaking off bear call</a></h4><ul> <li>Credit Suisse pushes JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='green'>+1.4%</font>) up to a Neutral rating from Underperform and lifts the price target on the airline stock by $3 to $19.</li> <li>The firm now sees 2020 expectations on JetBlue as more manageable with management making progress on cost controls.</li> <li>CS is now roughly in line with the sell-side consensus (Hold, PT $20.53) on JetBlue, while the <a href=\"https://seekingalpha.com/symbol/JBLU/ratings/quant-ratings\" target=\"_blank\">Seeking Alpha Quant Rating</a> on JBLU is still flashing Bullish.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476214\" data-linked=\"JetBlue gains after shaking off bear call\" data-tweet=\"$JBLU - JetBlue gains after shaking off bear call https://seekingalpha.com/news/3476214-jetblue-gains-after-shaking-off-bear-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3476214-jetblue-gains-after-shaking-off-bear-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>105&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476212\" data-ts=\"1562595362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCI\" target=\"_blank\">RCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476212-rogers-communicationsminus-1_6-jpmorgan-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rogers Communications -1.6% as JPMorgan cuts to Underweight</a></h4><ul>   <li>Rogers Communications (NYSE:<a href='https://seekingalpha.com/symbol/RCI' title='Rogers Communications Inc.'>RCI</a>) is <font color=\"red\">1.6% lower</font> after a cut to Underweight by JPMorgan, from Neutral.</li>    <li>The firm lowered its price target to C$69 from C$71, now implying 2% downside from Toronto pricing of C$70.37.</li>    <li>Average <a href=\"https://seekingalpha.com/symbol/RCI/ratings/sell-side-ratings\" target=\"_blank\">sell-side rating on Rogers is Hold</a>, and <a href=\"https://seekingalpha.com/symbol/RCI/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Bullish overall</a>. The stock has a <a href=\"https://seekingalpha.com/symbol/RCI/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476212\" data-linked=\"Rogers Communications -1.6% as JPMorgan cuts to Underweight\" data-tweet=\"$RCI - Rogers Communications -1.6% as JPMorgan cuts to Underweight https://seekingalpha.com/news/3476212-rogers-communicationsminus-1_6-jpmorgan-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3476212-rogers-communicationsminus-1_6-jpmorgan-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476208\" data-ts=\"1562594779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476208-viiv-healthcare-launches-u-s-study-on-implementation-of-monthly-hiv-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViiV Healthcare launches U.S. study on implementation of monthly HIV treatment</a></h4><ul><li>ViiV Healthcare <a href=\"https://www.viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-announces-start-of-first-ever-study-to-identify-and-evaluate-approaches-to-implementing-its-once-monthly-injectable-hiv-treatment-in-clinical-practice/\" target=\"_blank\">commences </a>a U.S.-based study, CUSTOMIZE, aimed at identifying and assessing the best ways to implement a once-monthly injectable treatment for HIV infection into clinical practice. The goal is to find the most practical and efficient ways to manage monthly treatment.</li><li>In April, ViiV submitted its marketing application to the FDA seeking approval for its once-monthly two-drug HIV regimen of cabotegravir and Janssen's rilpivirine. The agency's action date under Priority Review status is December 29.</li><li>ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a> <font color=\"red\">-0.5%</font>), Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"red\">-1.3%</font>) and Shionogi (<a href='https://seekingalpha.com/symbol/SGIOY' title='Shionogi & Co., Ltd.'>OTCPK:SGIOY</a> <font color=\"red\">-3.1%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3476208\" data-linked=\"ViiV Healthcare launches U.S. study on implementation of monthly HIV treatment\" data-tweet=\"$GSK $PFE $SGIOY - ViiV Healthcare launches U.S. study on implementation of monthly HIV treatment https://seekingalpha.com/news/3476208-viiv-healthcare-launches-u-s-study-on-implementation-of-monthly-hiv-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3476208-viiv-healthcare-launches-u-s-study-on-implementation-of-monthly-hiv-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476203\" data-ts=\"1562594208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476203-rosenblatt-cuts-apple-to-sell-seeing-fundamental-deterioration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt cuts Apple to Sell, seeing &#39;fundamental deterioration&#39;</a></h4><ul>   <li>Rosenblatt has cut Apple (<a href=\"http://seekingalpha.com/symbol/AAPL\" target=\"_blank\">AAPL</a> <font color=\"red\">-2.6%</font>) to Sell from Neutral, looking for \"fundamental deterioration\" over the next 6-12 months.</li>    <li>Specifically, new iPhone sales will be disappointing and iPad sales growth will slow in the second half, and sales from other products (HomePod, AirPod, Watch) may not be meaningful to total revenue growth, analyst Jun Zhang writes. Services sales growth won't be any help there either, Zhang says.</li>    <li>The firm's keeping its price target at $150, now implying 24.6% downside after Apple's recent run up (shares have gained 15% since a near-term low of $173.30 on June 3).</li>    <li>Meanwhile, most sell-side analysts are at <a href=\"https://seekingalpha.com/symbol/AAPL/ratings/sell-side-ratings\" target=\"_blank\">Outperform on average</a>, while <a href=\"https://seekingalpha.com/symbol/AAPL/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Bullish</a> and the stock has a <a href=\"https://seekingalpha.com/symbol/AAPL/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bullish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476203\" data-linked=\"Rosenblatt cuts Apple to Sell, seeing &#39;fundamental deterioration&#39;\" data-tweet=\"$AAPL - Rosenblatt cuts Apple to Sell, seeing &#39;fundamental deterioration&#39; https://seekingalpha.com/news/3476203-rosenblatt-cuts-apple-to-sell-seeing-fundamental-deterioration?source=tweet\" data-url=\"https://seekingalpha.com/news/3476203-rosenblatt-cuts-apple-to-sell-seeing-fundamental-deterioration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>134&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476187\" data-ts=\"1562593318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRWD\" target=\"_blank\">CRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476187-oppenheimer-outlines-bull-case-on-crowdstrike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer outlines bull case on CrowdStrike</a></h4><ul> <li>Oppenheimer was one of the firms that started off coverage on CrowdStrike (NASDAQ:<a href='https://seekingalpha.com/symbol/CRWD' title='CrowdStrike Holdings, Inc.'>CRWD</a>) with a <a href=\"https://seekingalpha.com/news/3476109-analysts-ratings-pour-crowdstrike\" target=\"_blank\">bullish rating</a> on its expectation for hypergrowth of over 30%.</li> <li>The firm points to CrowdStrike's \"innovative technology\" which layers on artificial intelligence/machine learning to crowdsourced threat intelligence to stay ahead of adversaries and its belief CRWD will continue to disrupt and gain market share from legacy and next-gen antivirus vendors.</li> <li>The industry's shift to consolidate point product solutions and shortage of cyber-skilled talents are also seen driving customers to seek a holistic solution like Crowdstrike's.</li> <li>Shares of Crowdstrike topped out at $79.79 following the IPO last month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476187\" data-linked=\"Oppenheimer outlines bull case on CrowdStrike\" data-tweet=\"$CRWD - Oppenheimer outlines bull case on CrowdStrike https://seekingalpha.com/news/3476187-oppenheimer-outlines-bull-case-on-crowdstrike?source=tweet\" data-url=\"https://seekingalpha.com/news/3476187-oppenheimer-outlines-bull-case-on-crowdstrike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476185\" data-ts=\"1562593146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476185-f5-networksminus-4_7-goldman-cuts-to-sell-on-pressures\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 Networks -4.7% as Goldman cuts to Sell on pressures</a></h4><ul>   <li>F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) has come out of today's open <font color=\"red\">down 4.7%</font> as Goldman Sachs cuts the shares to Sell, from Neutral.</li>    <li>The company is seeing weak short-term indications for spending in the enterprise market (which makes up almost two-thirds of F5 revenue), and <a href=\"https://seekingalpha.com/news/3471439-f5-minus-6_3-percent-vmware-avi-deal-expected-hit-adc-business\" target=\"_blank\">VMware has become a rival</a> with its recent M&amp;A, analyst Rod Hall notes.</li>    <li>He's cut his price target to $120 from $165, implying 14.7% further downside.</li>    <li>Sell-side analysts have a <a href=\"https://seekingalpha.com/symbol/FFIV/ratings/sell-side-ratings\" target=\"_blank\">Hold rating on average</a>; <a href=\"https://seekingalpha.com/symbol/FFIV/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a> as well, and the stock has a <a href=\"https://seekingalpha.com/symbol/FFIV/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476185\" data-linked=\"F5 Networks -4.7% as Goldman cuts to Sell on pressures\" data-tweet=\"$FFIV - F5 Networks -4.7% as Goldman cuts to Sell on pressures https://seekingalpha.com/news/3476185-f5-networksminus-4_7-goldman-cuts-to-sell-on-pressures?source=tweet\" data-url=\"https://seekingalpha.com/news/3476185-f5-networksminus-4_7-goldman-cuts-to-sell-on-pressures\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476172\" data-ts=\"1562592507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTAP\" target=\"_blank\">NTAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476172-netappminus-5_8-citi-cuts-to-sell-on-margin-pressures\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetApp -5.8% as Citi cuts to Sell on margin pressures</a></h4><ul>   <li>NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>) is <font color=\"red\">5.8% lower</font> premarket amid a cut to Sell at Citi, which points to increasing competition.</li>    <li>Q1 numbers (due Aug. 14) should come in line with expectations, but Q2 outlook could show the impact of pressure on margins, analyst Jim Suva writes. That comes from more pressure from the likes of Dell, HP Enterprise, Pure Storage and Nutanix.</li>    <li>He's cut his price target to $55 from $67, implying 12% downside.</li>    <li>While sell-side analysts rate NetApp <a href=\"https://seekingalpha.com/symbol/NTAP/ratings/sell-side-ratings\" target=\"_blank\">Outperform on average</a>, <a href=\"https://seekingalpha.com/symbol/NTAP/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a> and the stock has a <a href=\"https://seekingalpha.com/symbol/NTAP/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476172\" data-linked=\"NetApp -5.8% as Citi cuts to Sell on margin pressures\" data-tweet=\"$NTAP - NetApp -5.8% as Citi cuts to Sell on margin pressures https://seekingalpha.com/news/3476172-netappminus-5_8-citi-cuts-to-sell-on-margin-pressures?source=tweet\" data-url=\"https://seekingalpha.com/news/3476172-netappminus-5_8-citi-cuts-to-sell-on-margin-pressures\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476168\" data-ts=\"1562592000\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476168-adma-up-3-premarket-on-fda-ok-of-license-transfers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADMA up 3% premarket on FDA OK of license transfers</a></h4><ul><li>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics, Inc.'>ADMA</a>) is up <font color=\"green\">3%</font> premarket on average volume in reaction to the <a href=\"https://seekingalpha.com/pr/17564254-adma-biologics-receives-fda-approval-license-transfers-bivigam-nabi-hb\" target=\"_blank\">FDA's signoff</a> for the transfer of licenses for BIVIGAM and Nabi-HB from Biotest Pharmaceuticals to the company.</li><li>The license transfers were the final regulatory items from its <a href=\"https://seekingalpha.com/news/3271931-adma-bio-completes-biotest-asset-purchase\" target=\"_blank\">acquisition </a>of Biotest's Therapy Business Unit in June 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476168\" data-linked=\"ADMA up 3% premarket on FDA OK of license transfers\" data-tweet=\"$ADMA - ADMA up 3% premarket on FDA OK of license transfers https://seekingalpha.com/news/3476168-adma-up-3-premarket-on-fda-ok-of-license-transfers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476168-adma-up-3-premarket-on-fda-ok-of-license-transfers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476167\" data-ts=\"1562591993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARE\" target=\"_blank\">ARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476167-alexandria-real-estate-to-refinance-up-to-950m-of-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexandria Real Estate to refinance up to $950M of notes</a></h4><ul><li>Alexandria Real Estate Equities (NYSE:<a href='https://seekingalpha.com/symbol/ARE' title='Alexandria Real Estate Equities, Inc.'>ARE</a>) <a href=\"https://seekingalpha.com/pr/17564343-alexandria-real-estate-equities-inc-announces-public-offering-senior-notes\" target=\"_blank\">starts a public offering </a>of two tranches of senior notes and expects to use the proceeds to refinance its 2.75% senior notes due 2020 and its 4.60% senior notes due 2022.</li><li>ARE s<font color=\"red\">lips 2.1%</font> in premarket trading.</li><li>Any surplus proceeds, if any, will be used for general corporate purposes, which may include partial repayment of its senior bank term loan and reduction of its senior line of credit debt.</li><li>Starts <a href=\"https://seekingalpha.com/pr/17564344-alexandria-real-estate-equities-inc-announces-tender-offer-outstanding-2_750-percent-senior\" target=\"_blank\">cash tender offer </a>for any and all of the 2020 notes and the 2022 notes.</li><li>Currently has $400M of 2020 notes outstanding and $550M of the 2022 notes outstanding.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476167\" data-linked=\"Alexandria Real Estate to refinance up to $950M of notes\" data-tweet=\"$ARE - Alexandria Real Estate to refinance up to $950M of notes https://seekingalpha.com/news/3476167-alexandria-real-estate-to-refinance-up-to-950m-of-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/3476167-alexandria-real-estate-to-refinance-up-to-950m-of-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476164\" data-ts=\"1562591468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476164-ctst-cei-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTST, CEI among premarket losers</a></h4><ul><li>CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) <font color=\"red\">-20%</font> on <a href=\"https://seekingalpha.com/news/3476133-canntrust-15-percent-premarket-negative-regulatory-audit\" target=\"_blank\">negative regulatory audit</a>.</li><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/news/3476116-intra-cellular-9-percent-premarket-uneven-results-lumateperone-studies\" target=\"_blank\">uneven results</a> from lumateperone studies.</li><li>Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">-14%</font>.</li><li>Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"red\">-14%</font>.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-10%</font> on receiving <a href=\"https://seekingalpha.com/pr/17564226-camber-energy-inc-announces-notification-nyse-american-continued-listing-deficiency\" target=\"_blank\">non-compliance</a> notice and effectiveness of 1:25 reverse split.</li><li>Mobile TeleSystems Public Joint Stock (NYSE:<a href='https://seekingalpha.com/symbol/MBT' title='Mobile TeleSystems Public Joint Stock Company'>MBT</a>) <font color=\"red\">-5%</font>.</li><li>LG Display (NYSE:<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476164\" data-linked=\"CTST, CEI among premarket losers\" data-tweet=\"$CTST $ITCI $NOAH - CTST, CEI among premarket losers https://seekingalpha.com/news/3476164-ctst-cei-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476164-ctst-cei-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476163\" data-ts=\"1562591403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476163-oasm-blcm-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OASM, BLCM among premarket gainers</a></h4><ul><li>Oasmia Pharmaceutical AB (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical AB &#40;publ&#41;'>OASM</a>) <font color=\"green\">+22%</font>.</li><li>Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) <font color=\"green\">+17%</font> on <a href=\"https://seekingalpha.com/news/3476103-sangamo-14-percent-premarket-positive-hemophilia-gene-therapy-data\" target=\"_blank\">positive </a>hemophilia A gene therapy data.</li><li>Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) <font color=\"green\">+10%</font> on encouraging Natesto <a href=\"https://seekingalpha.com/news/3476110-aytu-bio-8-percent-premarket-encouraging-natesto-data\" target=\"_blank\">data</a>.</li><li>Bellicum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals, Inc.'>BLCM</a>) <font color=\"green\">+6%</font> as <a href=\"https://seekingalpha.com/pr/17564212-bellicum-pharmaceuticals-announces-rivo-cel-achieves-primary-endpoint-pediatric\" target=\"_blank\">Rivo-cel achieves</a> primary endpoint in pediatric registrational trial.</li><li>Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) <font color=\"green\">+6%</font>.</li><li>Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) <font color=\"green\">+5%</font> after Broadcom <a href=\"https://seekingalpha.com/news/3476121-symantec-plus-5-percent-broadcom-deal-advances\" target=\"_blank\">deal advances</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476163\" data-linked=\"OASM, BLCM among premarket gainers\" data-tweet=\"$OASM $SGMO $AYTU - OASM, BLCM among premarket gainers https://seekingalpha.com/news/3476163-oasm-blcm-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476163-oasm-blcm-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476161\" data-ts=\"1562590900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRVL\" target=\"_blank\">PRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476161-fda-fast-tracks-prevails-proo1-for-parkinsons-shares-up-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Fast Track&#39;s Prevail&#39;s PROO1 for Parkinson&#39;s; shares up 12% premarket</a></h4><ul><li>Prevail Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRVL' title='Prevail Therapeutics Inc.'>PRVL</a>) is up <font color=\"green\">12%</font> premarket on light volume on the heels of the FDA designating gene therapy PR001 for <a href=\"https://seekingalpha.com/pr/17564189-prevail-therapeutics-receives-u-s-fda-fast-track-designation-pr001-treatment-parkinson-s\" target=\"_blank\">Fast Track review</a> for the treatment of GBA1 mutation-positive Parkinson's disease patients.</li><li>Dosing in a Phase 1/2 study should commence in H2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476161\" data-linked=\"FDA Fast Track&#39;s Prevail&#39;s PROO1 for Parkinson&#39;s; shares up 12% premarket\" data-tweet=\"$PRVL - FDA Fast Track&#39;s Prevail&#39;s PROO1 for Parkinson&#39;s; shares up 12% premarket https://seekingalpha.com/news/3476161-fda-fast-tracks-prevails-proo1-for-parkinsons-shares-up-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3476161-fda-fast-tracks-prevails-proo1-for-parkinsons-shares-up-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476159\" data-ts=\"1562590758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476159-valeritasplus-5-premarket-on-positive-v-go-data-compared-to-mdi-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeritas+5% premarket on positive V-Go data as compared to MDI therapy</a></h4><ul> <li>Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <a href=\"https://seekingalpha.com/pr/17564035-valeritas-v-go-wearable-insulin-delivery-device-demonstrates-economic-advantages-compared\" target=\"_blank\">announces</a> positive data from a study comparing patients using V-Go to patients using multiple daily injection &#40;MDI&#41; therapy, for insulin dependent type 2 diabetes population.</li><li>The study demonstrates V-Go users experienced lower insulin dose requirements and lower diabetes-related medication cost while lowering average blood sugar levels, compared to MDI users.</li><li>Shares are up <font color=\"green\">5%</font> premarket.</li>       </ul><div class=\"tiny-share-widget\" data-id=\"3476159\" data-linked=\"Valeritas+5% premarket on positive V-Go data as compared to MDI therapy\" data-tweet=\"$VLRX - Valeritas+5% premarket on positive V-Go data as compared to MDI therapy https://seekingalpha.com/news/3476159-valeritasplus-5-premarket-on-positive-v-go-data-compared-to-mdi-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3476159-valeritasplus-5-premarket-on-positive-v-go-data-compared-to-mdi-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476158\" data-ts=\"1562590669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STT\" target=\"_blank\">STT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476158-bny-mellon-state-streetminus-2_3-morgan-stanley-turns-cautious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BNY Mellon, State Street -2.3% as Morgan Stanley turns cautious</a></h4><ul><li>Morgan Stanley analyst Betsy Graseck downgrades Bank of New York Mellon (NYSE:<a href='https://seekingalpha.com/symbol/BK' title='The Bank of New York Mellon Corporation'>BK</a>) and State Street (NYSE:<a href='https://seekingalpha.com/symbol/STT' title='State Street Corporation'>STT</a>) to underweight from overweight.</li><li>BNY Mellon <font color=\"red\">slumps 2.3%</font> in premarket trading as does State Street.</li><li>Large cap bank industry view cut to in-line from attractive.</li><li>BNY Mellon quant rating at <a href=\"https://seekingalpha.com/symbol/BK/ratings/quant-ratings\" target=\"_blank\">Neutral</a>; before this action, sell-side average rating was <a href=\"https://seekingalpha.com/symbol/BK/ratings/sell-side-ratings\" target=\"_blank\">Neutral </a>(3 Outperform, 15 Hold, 2 Underperform, 2 Sell).</li></ul><div class=\"tiny-share-widget\" data-id=\"3476158\" data-linked=\"BNY Mellon, State Street -2.3% as Morgan Stanley turns cautious\" data-tweet=\"$STT $BK $BK - BNY Mellon, State Street -2.3% as Morgan Stanley turns cautious https://seekingalpha.com/news/3476158-bny-mellon-state-streetminus-2_3-morgan-stanley-turns-cautious?source=tweet\" data-url=\"https://seekingalpha.com/news/3476158-bny-mellon-state-streetminus-2_3-morgan-stanley-turns-cautious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476156\" data-ts=\"1562590479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACB\" target=\"_blank\">ACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476156-canaccord-likes-rhythm-pharma-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord likes Rhythm Pharma in premarket analyst action</a></h4><ul><li>Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) initiated with Neutral rating at Compass Point. Shares down a fraction premarket.</li><li>Rhythm Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RYTM' title='Rhythm Pharmaceuticals, Inc.'>RYTM</a>) initiated with Buy rating and $35 (66% upside) price target at Canaccord Genuity.</li><li>PolarityTE (NASDAQ:<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a>) initiated with Buy rating and $8 (45% upside) price target at H.C. Wainwright. Shares up <font color=\"green\">2% </font>premarket.</li><li>Protagonist Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics, Inc.'>PTGX</a>) initiated with Buy rating and $23 (79% upside) price target at H.C. Wainwright.</li><li>Replimune (NASDAQ:<a href='https://seekingalpha.com/symbol/REPL' title='Replimune Group, Inc.'>REPL</a>) initiated with Buy rating and $26 (90% upside) price target at H.C. Wainwright.</li><li>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) downgraded to Neutral with a $48 (2% upside) price target at Cantor Fitzgerald.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476156\" data-linked=\"Canaccord likes Rhythm Pharma in premarket analyst action\" data-tweet=\"$ACB $RYTM $ARRY - Canaccord likes Rhythm Pharma in premarket analyst action https://seekingalpha.com/news/3476156-canaccord-likes-rhythm-pharma-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3476156-canaccord-likes-rhythm-pharma-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476153\" data-ts=\"1562590092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSP\" target=\"_blank\">INSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476153-unitedhealthcare-issues-coverage-for-inspire-medicals-therapy-for-osa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealthcare issues coverage for Inspire Medical&#39;s therapy for OSA</a></h4><ul> <li>UnitedHealthcare will <a href=\"https://seekingalpha.com/pr/17563989-inspire-medical-systems-inc-announces-unitedhealthcare-coverage-inspire-therapy-treatment\" target=\"_blank\">provide</a> coverage for Inspire Medical Systems' (NYSE:<a href='https://seekingalpha.com/symbol/INSP' title='Inspire Medical Systems, Inc.'>INSP</a>), Inspire therapy effective August 1, 2019.</li>  <li>Under its policy, UnitedHealthcare considers Inspire\u2019s FDA approved hypoglossal nerve neurostimulation device to be medically necessary for the treatment of moderate to severe obstructive sleep apnea &#40;OSA&#41; when specified criteria are met.</li><li>INSP now have 35 coverage policies, representing approx. 125M members.</li><li>Shares are up <font color=\"green\">7%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476153\" data-linked=\"UnitedHealthcare issues coverage for Inspire Medical&#39;s therapy for OSA\" data-tweet=\"$INSP - UnitedHealthcare issues coverage for Inspire Medical&#39;s therapy for OSA https://seekingalpha.com/news/3476153-unitedhealthcare-issues-coverage-for-inspire-medicals-therapy-for-osa?source=tweet\" data-url=\"https://seekingalpha.com/news/3476153-unitedhealthcare-issues-coverage-for-inspire-medicals-therapy-for-osa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476152\" data-ts=\"1562590037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476152-verizonminus-1-citi-sees-lower-wireless-pricing-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon -1% as Citi sees lower wireless pricing ahead</a></h4><ul><li>Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications Inc.'>VZ</a>) <font color=\"red\">-1%</font> premarket after Citi <a href=\"https://www.cnbc.com/2019/07/08/verizon-shares-fall-after-citi-downgrades-the-stock-predicting-lower-wireless-pricing-ahead.html\" target=\"_blank\">downgraded</a> the company to Neutral from Buy, saying returns over the next 12 months will likely be limited by a high valuation and \"rising long-term industry risks.\"</li><li>\"Verizon\u2019s consistently strong operating performance in the wireless category may not be enough to drive further multiple expansion at a time when investors are more likely to question the competitive environment and long-term risks to pricing and margins,\" said Michael Rollins, maintaining the stock's $62 price target.</li><li>A merger between T-Mobile and Sprint \"creates a potentially disruptive fourth competitor [that] could be dilutive to long-term pricing and margins for the wireless industry,\" he added.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476152\" data-linked=\"Verizon -1% as Citi sees lower wireless pricing ahead\" data-tweet=\"$VZ - Verizon -1% as Citi sees lower wireless pricing ahead https://seekingalpha.com/news/3476152-verizonminus-1-citi-sees-lower-wireless-pricing-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3476152-verizonminus-1-citi-sees-lower-wireless-pricing-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476133\" data-ts=\"1562587972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTST\" target=\"_blank\">CTST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476133-canntrust-down-15-premarket-on-negative-regulatory-audit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CannTrust down 15% premarket on negative regulatory audit</a></h4><ul><li>CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) is down <font color=\"red\">15%</font> premarket on modest volume in response to a <a href=\"https://seekingalpha.com/pr/17564054-canntrust-statement-regarding-health-canada-audit\" target=\"_blank\">recent audit</a> of its Pelham, Ontario greenhouse facility by Health Canada showing non-compliance with certain regulations.</li><li>Specifically, the company was growing cannabis in five unlicensed rooms during the period from October 2018 to March 2019 while its applications were under review (licenses were issued in April 2019). Company employees also provided inaccurate information to the regulator.</li><li>Health Canada has placed a hold on ~5,200 kg of dried cannabis that was harvested from the (then) unlicensed rooms until it confirms that the weed is compliant with regulations.</li><li>CannTrust has also voluntarily held ~7,500 kg of pot harvested at its Vaughan facility that was produced in previously unlicensed rooms until it can be verified as compliant.</li><li>Operations at both sites remain fully licensed at this point.</li><li>The company says that the holds may result in temporary product shortages for some customers, adding that it does not know, at this point, if the situation will affect financial results.</li><li>CEO Peter Aceto says, \"Our team has focused on building a culture of transparency, trust and excellence in every aspect of our business, including our interactions with the regulator. We have made many changes to make this right with Health Canada. We made errors in judgement, but the lessons we have learned here will serve us well moving forward.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3476133\" data-linked=\"CannTrust down 15% premarket on negative regulatory audit\" data-tweet=\"$CTST - CannTrust down 15% premarket on negative regulatory audit https://seekingalpha.com/news/3476133-canntrust-down-15-premarket-on-negative-regulatory-audit?source=tweet\" data-url=\"https://seekingalpha.com/news/3476133-canntrust-down-15-premarket-on-negative-regulatory-audit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476122\" data-ts=\"1562587077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBAN\" target=\"_blank\">HBAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476122-huntington-slips-1_5-after-bmo-goes-bearish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntington slips 1.5% after BMO goes bearish</a></h4><ul><li>Huntington Bancshares (NASDAQ:<a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a>)<font color=\"red\"> falls 1.5%</font> in premarket trading after BMO Capital Markets downgrades the bank to underperform from market perform.</li><li>BMO analyst Lana Chan notes \"less support than peers from stock buybacks in the 2019 CCAR cycle.\"</li><li>Also reduces earnings expectations on a lower rate environment and higher hedging costs.</li><li>Quant rating <a href=\"https://seekingalpha.com/symbol/HBAN/ratings/quant-ratings\" target=\"_blank\">Neutral</a>.</li><li>Downgrade makes BMO's call the sole bearish rating on HBAN; before this action, sell-side average rating was <a href=\"https://seekingalpha.com/symbol/HBAN/ratings/sell-side-ratings\" target=\"_blank\">Outperform</a> (5 Buy, 4 Outperform, 15 Hold).</li><li>In the past six months, Huntington <a href=\"https://seekingalpha.com/symbol/HBAN/momentum/performance\" target=\"_blank\">has risen </a>12.4% vs. financial sector median performance of 7.4%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476122\" data-linked=\"Huntington slips 1.5% after BMO goes bearish\" data-tweet=\"$HBAN - Huntington slips 1.5% after BMO goes bearish https://seekingalpha.com/news/3476122-huntington-slips-1_5-after-bmo-goes-bearish?source=tweet\" data-url=\"https://seekingalpha.com/news/3476122-huntington-slips-1_5-after-bmo-goes-bearish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476121\" data-ts=\"1562586896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476121-symantecplus-5-after-broadcom-deal-advances\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Symantec +5% after Broadcom deal advances</a></h4><ul> <li>Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) is <font color=\"green\">up 5.24%</font> to $26.31 in premarket trading on <a href=\"https://seekingalpha.com/news/3476077-broadcom-makes-progress-symantec-deal\" target=\"_blank\">reports</a> that Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) has made progress on securing financing for an acquisition.</li> <li>For its part, Broadcom sees annual synergy potential of around $1.5B if the deal comes off.</li> <li>AVGO <font color=\"red\">-0.62%</font> premarket to $280.90.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476121\" data-linked=\"Symantec +5% after Broadcom deal advances\" data-tweet=\"$NLOK $AVGO - Symantec +5% after Broadcom deal advances https://seekingalpha.com/news/3476121-symantecplus-5-after-broadcom-deal-advances?source=tweet\" data-url=\"https://seekingalpha.com/news/3476121-symantecplus-5-after-broadcom-deal-advances\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476116\" data-ts=\"1562586885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476116-intra-cellular-down-9-premarket-on-uneven-results-from-lumateperone-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular down 9% premarket on uneven results from lumateperone studies</a></h4><ul><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) slips <font color=\"red\">9%</font> premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/17564033-intra-cellular-therapies-announces-positive-top-line-results-phase-3-trial-lumateperone\" target=\"_blank\">announcement </a>of results from two Phase 3 clinical trials evaluating lumateperone in patients with bipolar depression.</li><li><a href=\"https://clinicaltrials.gov/ct2/show/NCT03249376?lead=intra-cellular+therapies&amp;phase=2&amp;rank=1\" target=\"_blank\">Study 404</a> met the primary endpoint of a statistically significant change in Montgomery-Åsberg Depression Rating Scale &#40;MADRS&#41; total score versus placebo (p&lt;0.001). Key secondary endpoints were also met.</li><li><a href=\"https://clinicaltrials.gov/ct2/show/NCT02600494?lead=intra-cellular+therapies&amp;phase=2&amp;rank=4\" target=\"_blank\">Study 401</a>, however, failed to achieve the primary endpoint due to an unexpectedly high response rate in the placebo arm. Specifically, patients receiving the 42 mg dose or the 28 mg dose of lumateperone showed least squares &#40;LS&#41; mean reductions from baseline in MADRS score of 20.7 points and 18.9 points compared to 19.7 points for control.</li><li>No new safety signals were observed.</li><li>Additional results will be released in the near future.</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476116\" data-linked=\"Intra-Cellular down 9% premarket on uneven results from lumateperone studies\" data-tweet=\"$ITCI - Intra-Cellular down 9% premarket on uneven results from lumateperone studies https://seekingalpha.com/news/3476116-intra-cellular-down-9-premarket-on-uneven-results-from-lumateperone-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3476116-intra-cellular-down-9-premarket-on-uneven-results-from-lumateperone-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476109\" data-ts=\"1562585094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRWD\" target=\"_blank\">CRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476109-analysts-ratings-pour-in-on-crowdstrike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts ratings pour in on CrowdStrike</a></h4><ul> <li>Early analyst coverage on CrowdStrike Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CRWD' title='CrowdStrike Holdings, Inc.'>CRWD</a>) leans heavily to the bullish side.</li> <li>Positive ratings are in from Bank of America Merrill Lynch (Buy), Mizuho (Buy), Needham (Buy), Stifel (Buy), JMP (Outperform), Macquarie (Outperform), Barclays (Outperform) and JPMorgan (Outperform). The highest price targets from the bunch were from JPMorgan at $100 and Oppenheimer at $90.</li> <li>More cautious ratings are in from Jefferies (Hold, $71 PT), SunTrust (Hold, $69 PT) and Credit Suisse (Neutral, $70 PT).</li> <li>CRWD <font color=\"green\">+1.03%</font> premarket to $67.90 to stand almost 100% over the IPO pricing level on the tech stock of $34.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476109\" data-linked=\"Analysts ratings pour in on CrowdStrike\" data-tweet=\"$CRWD - Analysts ratings pour in on CrowdStrike https://seekingalpha.com/news/3476109-analysts-ratings-pour-in-on-crowdstrike?source=tweet\" data-url=\"https://seekingalpha.com/news/3476109-analysts-ratings-pour-in-on-crowdstrike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476110\" data-ts=\"1562585094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476110-aytu-bio-up-8-premarket-on-encouraging-natesto-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio up 8% premarket on encouraging Natesto data</a></h4><ul> <li>Aytu BioScience's (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) study titled, Efficacy of Nasal Testosterone Gel (Natesto) Stratified by Baseline Endogenous Testosterone Levels, achieves similar <a href=\"https://seekingalpha.com/pr/17563962-aytu-bioscience-announces-publication-clinical-study-results-demonstrating-effectiveness\" target=\"_blank\">symptom improvement</a>, regardless of the degree of patients\u2019 testosterone deficiency, while maintaining function of the Hypothalamic-Pituitary-Gonadal &#40;HPG&#41; axis in hypogonadal men.</li> <li>The Phase 3 study enrolled 306 patients, who were treated with Natesto for up to one year. Each dose of Natesto resulted in a short-term return of testosterone to the upper normal range (800 ng/dL) irrespective of how low the patient\u2019s baseline testosterone was prior to the study.</li> <li>A mean average serum testosterone level of 295 ng/dL was achieved, in patients with the lowest baseline testosterone level.</li><li>Statistically significant improvements in symptom relief (erectile function, mood and lean body mass) were observed in these patients.</li><li>Shares are up <font color=\"green\">8%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476110\" data-linked=\"Aytu Bio up 8% premarket on encouraging Natesto data\" data-tweet=\"$AYTU - Aytu Bio up 8% premarket on encouraging Natesto data https://seekingalpha.com/news/3476110-aytu-bio-up-8-premarket-on-encouraging-natesto-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3476110-aytu-bio-up-8-premarket-on-encouraging-natesto-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476090\" data-ts=\"1562584195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476090-catalyst-bios-marzaa-successful-in-mid-stage-hemophilia-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio&#39;s MarzAA successful in mid-stage hemophilia study</a></h4><ul> <li>A Phase 2 trial of Catalyst Biosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) subcutaneous &#40;SQ&#41; Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for prophylaxis <a href=\"https://seekingalpha.com/pr/17563929-catalyst-biosciences-meets-primary-endpoint-reduction-annualized-bleeding-rate-phase-2-trial\" target=\"_blank\">met the primary endpoint</a> of significantly reducing the annualized bleed rate &#40;ABR&#41; in patients with hemophilia A or B with inhibitors.</li><li>The study also met all secondary endpoints of safety, tolerability and lack of anti-drug antibody or inhibitor formation.</li>      <li>Daily SQ administration for 50 days at an individual\u2019s final dose of MarzAA significantly reduced the mean 6-month pre-study ABR from 19.8 to 1.6 and Proportion of Days with Bleeding &#40;PDB&#41;, from 12.3% to 0.8%, during treatment.</li><li>The median ABR and PDB were both reduced to zero.</li><li>The Company will host a conference call today, at 8:00 a.m. EDT to discuss the MarzAA and DalcA data.</li><li>Shares are down <font color=\"red\">2%</font> premarket.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3476090\" data-linked=\"Catalyst Bio&#39;s MarzAA successful in mid-stage hemophilia study\" data-tweet=\"$CBIO - Catalyst Bio&#39;s MarzAA successful in mid-stage hemophilia study https://seekingalpha.com/news/3476090-catalyst-bios-marzaa-successful-in-mid-stage-hemophilia-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3476090-catalyst-bios-marzaa-successful-in-mid-stage-hemophilia-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476104\" data-ts=\"1562583915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECA\" target=\"_blank\">ECA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476104-encana-to-sell-arkoma-nat-gas-assets-starts-stock-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Encana to sell Arkoma nat gas assets, starts stock buyback</a></h4><ul><li>Encana (NYSE:<a href='https://seekingalpha.com/symbol/ECA' title='Encana Corporation'>ECA</a>) <font color=\"green\">rises 1.0% </font>in premarket trading after<a href=\"https://seekingalpha.com/pr/17563970-encana-signs-agreement-sell-arkoma-basin-natural-gas-assets\" target=\"_blank\"> agreeing</a> to sell its natural gas assets in Oklahoma's Arkoma Basin for ~C$165M (US$126M) in cash and starting its previously announced <a href=\"https://seekingalpha.com/pr/17563982-encana-announces-commencement-us-213-million-substantial-issuer-bid\" target=\"_blank\">substantial issuer bid</a> to buy up to US$213M of its common shares.</li><li>Sees sale to undisclosed buyer closing in Q3.</li><li>Encana's Arkoma assets include ~140,000 net acres of leasehold and current production of ~77M cubic feet equivalent per day (98% natural gas).</li><li>Substantial issuer bid is being conducted as a \"modified Dutch auction\" at US$4.70-US$5.40 per share; offer expires at 5:00 PM ET on Aug. 14, 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476104\" data-linked=\"Encana to sell Arkoma nat gas assets, starts stock buyback\" data-tweet=\"$ECA - Encana to sell Arkoma nat gas assets, starts stock buyback https://seekingalpha.com/news/3476104-encana-to-sell-arkoma-nat-gas-assets-starts-stock-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3476104-encana-to-sell-arkoma-nat-gas-assets-starts-stock-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476103\" data-ts=\"1562583859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476103-sangamo-up-14-premarket-on-positive-hemophilia-gene-therapy-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo up 14% premarket on positive hemophilia A gene therapy data</a></h4><ul><li>Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) is up <font color=\"green\">14%</font> premarket on light volume in response to <a href=\"https://seekingalpha.com/pr/17551945-sangamo-announces-upcoming-presentation-investigational-sbminus-525-hemophilia-gene-therapy\" target=\"_blank\">updated results</a> from the Phase 1/2 ALTA study evaluating gene therapy SB-525 in patients with severe hemophilia A. The data were presented at the International Society on Thrombosis and Hemostasis Congress in Melbourne.</li><li>The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal sustained factor VIII levels with no reported bleeding events and no factor usage during the 24 weeks of follow-up. Two additional patients recently treated showed comparable results at similar early time points.</li><li>SB-525 was generally well-tolerated and demonstrated dose-dependent increases in factor VIII activity levels.</li><li>Collaboration partner Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) is unchanged in premarket action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476103\" data-linked=\"Sangamo up 14% premarket on positive hemophilia A gene therapy data\" data-tweet=\"$SGMO $PFE - Sangamo up 14% premarket on positive hemophilia A gene therapy data https://seekingalpha.com/news/3476103-sangamo-up-14-premarket-on-positive-hemophilia-gene-therapy-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3476103-sangamo-up-14-premarket-on-positive-hemophilia-gene-therapy-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476099\" data-ts=\"1562583280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNWGY\" target=\"_blank\">CNWGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476099-cineworldplus-2-after-rbc-capital-points-to-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cineworld +2% after RBC Capital points to upside</a></h4><ul> <li>Shares of Cineworld Group (<a href='https://seekingalpha.com/symbol/CNWGY' title='Cineworld Group PLC ADR'>OTC:CNWGY</a>) are tracking higher after RBC Capital calls the cinema chain undervalued.</li> <li>The firm also thinks Cineworld could be an acquisition target.</li> <li>\"The falling share price caused by the film release schedule that is driving short-term earnings weakness suggests the stock would be a better vehicle for investors with a longer-term time horizon. In addition to strong returns, private equity would benefit from the long-term potential for Regal from a management team that trebled the Cineworld share price after taking control in 2014,\" notes RBC's analyst team.</li> <li>Cineworld <font color=\"green\">+2.36%</font> in London trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476099\" data-linked=\"Cineworld +2% after RBC Capital points to upside\" data-tweet=\"$CNWGY - Cineworld +2% after RBC Capital points to upside https://seekingalpha.com/news/3476099-cineworldplus-2-after-rbc-capital-points-to-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3476099-cineworldplus-2-after-rbc-capital-points-to-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476097\" data-ts=\"1562582800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476097-fundamental-deterioration-sees-rosenblatt-downgrade-apple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Fundamental deterioration&#39; sees Rosenblatt downgrade Apple</a></h4><ul><li>\"After strong service revenue growth over the last 4 to 6 quarters and the launch of Apple Music and news, we believe service revenue growth will also decelerate,\" Rosenblatt Securities <a href=\"https://www.cnbc.com/2019/07/08/rosenblatt-downgrades-apple.html\" target=\"_blank\">said</a> Monday, downgrading Apple to Sell from Neutral but keeping its $150 PT intact.</li><li>\"Adding to our 'sell' thesis, we believe new iPhone sales will be disappointing, iPad sales growth will slow in the second half of 2019, other product sales growth, such as the HomePod, AirPod, and iWatch, may not be meaningful to support total revenue growth.\"</li><li>AAPL <font color=\"red\">-1.7%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3476097\" data-linked=\"&#39;Fundamental deterioration&#39; sees Rosenblatt downgrade Apple\" data-tweet=\"&#39;Fundamental deterioration&#39; sees Rosenblatt downgrade Apple https://seekingalpha.com/news/3476097-fundamental-deterioration-sees-rosenblatt-downgrade-apple?source=tweet\" data-url=\"https://seekingalpha.com/news/3476097-fundamental-deterioration-sees-rosenblatt-downgrade-apple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":59,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}